Remogliflozin etabonate

Remogliflozin, a novel, highly selective inhibitor of sodium-glucose cotransporter subtype 2 (SGLT2)

Indications

Type 2 diabetes mellitus

Dosage

oral; 100mg twice a day

Contra-Indications

Hypersensitivity

Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Data not sufficient Elderly: Data not sufficient

Side Effects

Low blood sugar (hypoglycemia), Urinary tract infections, Nervousness or anxiety, Irritability to sweat, Weight loss, Dizziness or headache, Fatigue, genital fungal infection

Drug Interactions

other hypoglycemic drugs